NASDAQ:CANFCan-Fite Biopharma Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Can-Fite Biopharma Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.89 +0.14 (+8.00 %) (As of 07/7/2020 04:00 PM ET) Add Compare Share Today's Range$1.75Now: $1.89▼$1.9350-Day Range$1.67MA: $1.97▼$2.5052-Week Range$1.08Now: $1.89▼$4.95Volume1.05 million shsAverage Volume1.06 million shsMarket Capitalization$16.39 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsHeadlinesOptions ChainSocial Media Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company's lead drug candidate is CF101, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 that is in Phase II clinical trials for the treatment of liver cancer and non-alcoholic fatty liver diseases, as well as for hepatocellular carcinoma and hepatitis C virus diseases; and CF602, which is in pre-clinical trial for the treatment of sexual dysfunction. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Can-Fite Biopharma. Previous Next 2.5 Community Rank Outperform VotesCan-Fite Biopharma has received 106 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCan-Fite Biopharma has received 104 “underperform” votes. (Add your “underperform” vote.)Community SentimentCan-Fite Biopharma has received 50.48% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Can-Fite Biopharma and other stocks. Vote “Outperform” if you believe CANF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CANF will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCan-Fite Biopharma does not currently pay a dividend.Dividend GrowthCan-Fite Biopharma does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Can-Fite Biopharma insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.50 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CANF Previous Symbol CUSIPN/A CIKN/A Webwww.canfite.co.il PhoneN/ADebt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares8,670,000Market Cap$16.39 million Next Earnings Date9/4/2020 (Estimated) OptionableOptionable NASDAQ:CANF Rates by TradingView Receive CANF News and Ratings via Email Sign-up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter. Can-Fite Biopharma (NASDAQ:CANF) Frequently Asked Questions How has Can-Fite Biopharma's stock been impacted by COVID-19 (Coronavirus)? Can-Fite Biopharma's stock was trading at $1.52 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CANF stock has increased by 24.3% and is now trading at $1.89. View which stocks have been most impacted by Coronavirus. When is Can-Fite Biopharma's next earnings date? Can-Fite Biopharma is scheduled to release its next quarterly earnings announcement on Friday, September 4th 2020. View our earnings forecast for Can-Fite Biopharma. Has Can-Fite Biopharma been receiving favorable news coverage? News stories about CANF stock have been trending negative on Tuesday, InfoTrie reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Can-Fite Biopharma earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news about Can-Fite Biopharma. Who are some of Can-Fite Biopharma's key competitors? Some companies that are related to Can-Fite Biopharma include Promis Neurosciences (PMN), Sirona Biochem (SBM), Immutep (IMM), Synairgen (SNG), Oxford Biodynamics (OBD), e-Therapeutics (ETX), Verona Pharma (VRP), Navidea Biopharmaceuticals (NAVB), Mereo BioPharma Group (MPH), Aerpio Pharmaceuticals (ARPO), Medlab Clinical (MDC), Equillium (EQ), Protalix Biotherapeutics (PLX), Memphasys (MEM) and OptiBiotix Health (OPTI). View all competitors. What other stocks do shareholders of Can-Fite Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Can-Fite Biopharma investors own include Allena Pharmaceuticals (ALNA), Heat Biologics (HTBX), Energy Transfer LP Unit (ET), Galmed Pharmaceuticals (GLMD), Genocea Biosciences (GNCA), Ovid Therapeutics (OVID), Sorrento Therapeutics (SRNE), Achieve Life Sciences (ACHV), ADMA Biologics (ADMA) and Amplify Energy (AMPY). Who are Can-Fite Biopharma's key executives? Can-Fite Biopharma's management team includes the following people: Prof. Pnina Fishman Ph.D., Scientific Founder, Chief Exec. Officer & Director (Age 70)Mr. Motti Farbstein, Chief Operating & Financial Officer (Age 54)Dr. Ilan Cohn Ph.D., Co-Founder & Chairman (Age 64)Dr. Michael H. Silverman M.D., F.A.C.P.,FACR, Medical DirectorDr. Vibeke Strand M.D., FACP, FACR (USA), Sr. Clinical Advisor What is Can-Fite Biopharma's stock symbol? Can-Fite Biopharma trades on the NASDAQ under the ticker symbol "CANF." How do I buy shares of Can-Fite Biopharma? Shares of CANF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Can-Fite Biopharma's stock price today? One share of CANF stock can currently be purchased for approximately $1.89. How big of a company is Can-Fite Biopharma? Can-Fite Biopharma has a market capitalization of $16.39 million. What is Can-Fite Biopharma's official website? The official website for Can-Fite Biopharma is www.canfite.co.il. This page was last updated on 7/7/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
